Today: 31 January 2026
Subscribe
Browse Category

NASDAQ:ALT News 31 January 2026

Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus

Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus

New York, Jan 31, 2026, 05:55 EST — The market has closed. Altimmune (ALT.O) shares ended Friday’s session at $5.60, roughly 10% higher, with the stock fluctuating between $5.00 and $5.65 during the day. Trading volume hit around 6.3 million shares. U.S. markets are closed for the weekend, but come Monday investors will have two key updates: a fresh cash…
31 January 2026
····

Stock Market Today

  • Novartis (SWX:NOVN) Seen Undervalued Despite Strong Multi-Year Gains
    January 31, 2026, 11:19 AM EST. Novartis shares trade around $114.62 after a 0.9% pullback in the past week and a 1-year return of 24.2%, lagging peers. The pharmaceutical giant boasts 70.3% returns over three years and 80% over five years. Our Discounted Cash Flow (DCF) model, projecting future cash flows until 2030, values Novartis stock at $254.07 per share, suggesting a 54.9% undervaluation versus the current price. With free cash flow projected to rise from $18.2 billion to $21.2 billion by 2030, the company's valuation looks attractive. The price-to-earnings (P/E) ratio complements this view, linking share price to earnings growth and risk. Novartis scores 5 out of 6 on undervaluation metrics, supporting the case for potential entry or hold for investors.
Go toTop